169 related articles for article (PubMed ID: 28692379)
41. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
[TBL] [Abstract][Full Text] [Related]
42. Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis.
Monga J; Subramani D; Bharathan A; Ghosh J
Sci Rep; 2020 Apr; 10(1):6649. PubMed ID: 32313135
[TBL] [Abstract][Full Text] [Related]
43. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
44. Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells.
Lin CY; Huo C; Kuo LK; Hiipakka RA; Jones RB; Lin HP; Hung Y; Su LC; Tseng JC; Kuo YY; Wang YL; Fukui Y; Kao YH; Kokontis JM; Yeh CC; Chen L; Yang SD; Fu HH; Chen YW; Tsai KK; Chang JY; Chuu CP
PLoS One; 2013; 8(6):e65734. PubMed ID: 23785446
[TBL] [Abstract][Full Text] [Related]
45. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV
Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206
[TBL] [Abstract][Full Text] [Related]
46. Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine-seeking behaviour.
Brice-Tutt AC; Wilson LL; Eans SO; Stacy HM; Simons CA; Simpson GG; Coleman JS; Ferracane MJ; Aldrich JV; McLaughlin JP
Br J Pharmacol; 2020 Sep; 177(18):4209-4222. PubMed ID: 32562259
[TBL] [Abstract][Full Text] [Related]
47. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells.
Jagadeesh S; Kyo S; Banerjee PP
Cancer Res; 2006 Feb; 66(4):2107-15. PubMed ID: 16489011
[TBL] [Abstract][Full Text] [Related]
48. Momordin Ic induces G0/1 phase arrest and apoptosis in colon cancer cells by suppressing SENP1/c-MYC signaling pathway.
Xianjun F; Xirui X; Jie T; Huiwen M; Shaojun Z; Qiaoyun L; Yunxin L; Xuqun S
J Pharmacol Sci; 2021 Aug; 146(4):249-258. PubMed ID: 34049792
[TBL] [Abstract][Full Text] [Related]
49. Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides.
Chatterjee S; Brite KH; Matsumura A
Clin Cancer Res; 2001 Oct; 7(10):3006-11. PubMed ID: 11595688
[TBL] [Abstract][Full Text] [Related]
50. Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity.
Mijatovic T; De Nève N; Gailly P; Mathieu V; Haibe-Kains B; Bontempi G; Lapeira J; Decaestecker C; Facchini V; Kiss R
Mol Cancer Ther; 2008 May; 7(5):1285-96. PubMed ID: 18483316
[TBL] [Abstract][Full Text] [Related]
51. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.
Yang G; Goltsov AA; Ren C; Kurosaka S; Edamura K; Logothetis R; DeMayo FJ; Troncoso P; Blando J; DiGiovanni J; Thompson TC
Mol Cancer Res; 2012 Feb; 10(2):218-29. PubMed ID: 22144662
[TBL] [Abstract][Full Text] [Related]
52. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells.
Xiao D; Johnson CS; Trump DL; Singh SV
Mol Cancer Ther; 2004 May; 3(5):567-75. PubMed ID: 15141014
[TBL] [Abstract][Full Text] [Related]
53. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
54. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells.
Itkonen HM; Urbanucci A; Martin SE; Khan A; Mathelier A; Thiede B; Walker S; Mills IG
Theranostics; 2019; 9(8):2183-2197. PubMed ID: 31149037
[TBL] [Abstract][Full Text] [Related]
55. CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling.
Zhang C; Gao C; Xu Y; Zhang Z
Gene; 2014 Aug; 546(1):73-9. PubMed ID: 24835310
[TBL] [Abstract][Full Text] [Related]
56. Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.
Sun JY; Wang JD; Wang X; Liu HC; Zhang MM; Liu YC; Zhang CH; Su Y; Shen YY; Guo YW; Shen AJ; Geng MY
Acta Pharmacol Sin; 2017 Apr; 38(4):551-560. PubMed ID: 28112184
[TBL] [Abstract][Full Text] [Related]
57. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
[TBL] [Abstract][Full Text] [Related]
58. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
Fan L; Peng G; Sahgal N; Fazli L; Gleave M; Zhang Y; Hussain A; Qi J
Oncogene; 2016 May; 35(19):2441-52. PubMed ID: 26279298
[TBL] [Abstract][Full Text] [Related]
59. RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Oehler-Jänne C; Arnold L; Stearns D; Eberhart CG; Arcaro A; Pruschy M; Grotzer MA
BMC Cancer; 2009 Jan; 9():10. PubMed ID: 19134217
[TBL] [Abstract][Full Text] [Related]
60. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
